Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

NNNN

Anbio Biotechnology

May 29 • 04:00PM ET

34.41

-0.03 -0.09 %

Healthcare • Medical Instruments & Supplies • Germany • Mid • NASD

Peers: AVTR TFX ICUI BAX BDX RMD MASI EW BSX MDT

Scroll to Statements

Index	-	P/E	210.20	EPS (ttm)	0.16	Insider Own	9.57%	Shs Outstand	43.89M	Perf Week	13.75%
Market Cap	4.95B	Forward P/E	-	EPS next Y	-	Insider Trans	0.00%	Shs Float	39.69M	Perf Month	25.45%
Enterprise Value	4.94B	PEG	-	EPS next Q	-	Inst Own	0.11%	Short Float	0.23%	Perf Quarter	33.58%
Income	7.19M	P/S	508.35	EPS this Y	-	Inst Trans	0.96%	Short Ratio	3.15	Perf Half Y	58.21%
Sales	9.74M	P/B	42.65	EPS next Y	-	ROA	26.08%	Short Interest	0.09M	Perf YTD	14.43%
Book/sh	0.81	P/C	354.17	EPS next 5Y	-	ROE	27.01%	52W High	55.65 -38.17%	Perf Year	344.00%
Cash/sh	0.10	P/FCF	-	EPS past 3/5Y	-12.86% 23.44%	ROIC	20.29%	52W Low	7.67 348.63%	Perf 3Y	-
Dividend Est.	-	EV/EBITDA	761.93	Sales past 3/5Y	-26.67% 16.85%	Gross Margin	87.06%	Volatility	11.65% 10.05%	Perf 5Y	-
Dividend TTM	-	EV/Sales	506.91	EPS Y/Y TTM	170.13%	Oper. Margin	66.47%	ATR (14)	2.98	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	344.31	Sales Y/Y TTM	10.10%	Profit Margin	73.75%	RSI (14)	69.20	Recom	-
Dividend Gr. 3/5Y	- -	Current Ratio	344.31	EPS Q/Q	321.09%	SMA20	17.73%	Beta	4.37	Target Price	-
Payout	0.00%	Debt/Eq	0.00	Sales Q/Q	87.39%	SMA50	25.47%	Rel Volume	0.28	Prev Close	34.44
Employees	27	LT Debt/Eq	0.00	Earnings	-	SMA200	14.30%	Avg Volume	29.39K	Price	34.41
IPO	Feb 19, 2025	Option/Short	No / Yes	EPS/Sales Surpr.	- -	Trades		Volume	8,191	Change	-0.09%

Mar-17-26 04:30PM	Anbio Biotechnology to Participate in KeyBanc Capital Markets Healthcare Forum (GlobeNewswire)
Jan-26-26 01:12PM	Stock Market Today: Trump's Medicare announcement slams health insurers (TheStreet) -24.73%
Aug-08-25 09:05PM	Anbio Biotechnology Responds to Global Outbreaks with Chikungunya Rapid Test and New 15-Minute Ultra-Fast PCR System (GlobeNewswire) +10.88% -7.89%
Jul-09-25 10:31AM	Here Is What You Need To Know Before Investing In Anbio Biotechnology (NNNN) (Insider Monkey) +14.50%
Jul-04-25 06:00AM	The IPO market in 2025 is being driven by a clear theme bigger is better (Yahoo Finance)
01:05AM	Loading…
May-15-25 01:05AM	Anbio Biotechnology to Showcase Global Diagnostic Innovations at Three Major May Exhibitions (GlobeNewswire) +6.12%
Feb-20-25 09:50AM	Anbio Biotechnology Announces Closing of Initial Public Offering (GlobeNewswire)
Feb-18-25 06:10PM	Anbio Biotechnology Announces Pricing of Initial Public Offering (GlobeNewswire)

Anbio Biotechnology is a medical device company. It is focused on developing and manufacturing a range of in-vitro diagnostic (IVD) products. The company was founded on July 27, 2021 and is headquartered in Frankfurt, Germany.

Ph.D.Mr. Michael Lau M.B.A.

Chief Financial OfficerMs. Suki Song CPA

Chief Business OfficerMr. Chris Tian

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

NNNN

Anbio Biotechnology

Upgrade your Finviz experience